{"id":"NCT03402841","sponsor":"AstraZeneca","briefTitle":"Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients","officialTitle":"A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-30","primaryCompletion":"2020-10-02","completion":"2022-03-10","firstPosted":"2018-01-18","resultsPosted":"2021-10-11","lastUpdate":"2024-08-21"},"enrollment":279,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Germline BRCA Mutated Ovarian Cancer"],"interventions":[{"type":"DRUG","name":"Olaparib","otherNames":["Lynparza"]}],"arms":[{"label":"Olaparib","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to assess the efficacy and safety of single-agent olaparib as a maintenance treatment in patients with relapsed High Grade Serous Ovarian Cancer (including patients with primary peritoneal and/or fallopian tube cancer) or high grade endometrioid cancer who do not have known deleterious or suspected deleterious germline BRCA mutations (non-gBRCAm) and who had responded following platinum based chemotherapy","primaryOutcome":{"measure":"Progression Free Survival (PFS)","timeFrame":"Up to maximum of 32 months","effectByArm":[{"arm":"Olaparib","deltaMin":9.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":8},"locations":{"siteCount":91,"countries":["Austria","Belgium","Bulgaria","Canada","Czechia","Denmark","Finland","Israel","Italy","Netherlands","Norway","Poland","Portugal","Romania","Slovenia","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["19553641","18971340","23118055","27717299","21821475","19383921","22452356","28754483","39695768","35063276","31553234"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00020&amp;attachmentIdentifier=486daa20-bd4a-47b0-bc50-4a91568f722f&amp;fileName=d0816c00020-csp-v-3_Final_Draft_13Sep21_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00020&amp;attachmentIdentifier=481a4401-0306-4d17-a5fc-edfdd6258606&amp;fileName=d0816c00020-sap-v-2_Final_Draft_13Sep21_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00020&amp;attachmentIdentifier=9826555e-52bc-47f7-9750-58a3f471bb4a&amp;fileName=d0816c00020-study-synopsis-pa_Final_Draft_13Sep21_Redacted.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D0816C00020&amp;attachmentIdentifier=597429d8-3f37-49d5-bd20-89cdcf0edd1d&amp;fileName=D0816C00020_CSR_Synopsis_Redacted.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":58,"n":279},"commonTop":["Nausea","Anaemia","Fatigue","Asthenia","Vomiting"]}}